HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment
Wasting (malnutrition) and lipodystrophy are the two major nutritional alterations in human immunodeficiency virus (HIV)-infected individuals. Both wasting and lipodystrophy may involve a decrease in body fat content, while wasting-but not lipodystrophy-also includes the loss of lean body mass. Lipo...
Gespeichert in:
| Veröffentlicht in: | AIDS patient care and STDs 2001-08, Vol.15 (8), p.411-423 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 423 |
|---|---|
| container_issue | 8 |
| container_start_page | 411 |
| container_title | AIDS patient care and STDs |
| container_volume | 15 |
| creator | Polsky, B Kotler, D Steinhart, C |
| description | Wasting (malnutrition) and lipodystrophy are the two major nutritional alterations in human immunodeficiency virus (HIV)-infected individuals. Both wasting and lipodystrophy may involve a decrease in body fat content, while wasting-but not lipodystrophy-also includes the loss of lean body mass. Lipodystrophy has made the identification of wasting increasingly more difficult. The diagnosis of wasting depends on a definition of the condition that takes into account sex and cultural differences, as well as measurements of body cell mass. Patient management involves a concurrent, comprehensive approach designed to restore lost body cell mass and weight. The authors make recommendations for defining, diagnosing, and treating HIV-associated wasting. Specific therapies include testosterone replacement, other anabolic steroids, and recombinant human growth hormone. Other adjunctive measures, such as progressive resistance exercise and cytokine modulation, may also be utilized. Expected outcomes from effective treatment include restored body cell mass, improvement in quality of life, and reduced rates of hospitalization. Future directions for research should address the need for optimal treatment strategies. |
| doi_str_mv | 10.1089/108729101316914412 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71123409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71123409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-e38219ea69c4526f727829bcfbe705940efe52034f720d9b96f3acc981fb747f3</originalsourceid><addsrcrecordid>eNqFkU9LAzEQxYMotv75Ah4kePDU1Uw22Wy8laJWKAhSPQlLdndSI-1uTXYRv70pLQh68DIz8H5vYOYRcgbsCliur2NRXAODFDINQgDfI0OQUiVKCL0f5wgkkRADchTCO2Ms55IdkgGA5JyDHJLX6cNLYkJoK2c6rOmnCZ1rFtQ1tHtDOh2Pn-YUvbmhi97VuHQNBmpbT6MHQ1hh041o7cyiaYMLI2qamnYeTbdRTsiBNcuAp7t-TJ7vbueTaTJ7vH-YjGdJlUrVJZjmHDSaTFdC8swqrnKuy8qWqJjUgqFFyVkqosJqXerMpqaqdA62VELZ9JhcbveuffvRY-iKlQsVLpemwbYPhQLgqWD6XxByiO-ELIIXv8D3tvdNPKLgPMtVpDYQ30KVb0PwaIu1dyvjvwpgxSah4m9C0XS-29yXK6x_LLtI0m-wD4lX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>226871016</pqid></control><display><type>article</type><title>HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>Polsky, B ; Kotler, D ; Steinhart, C</creator><creatorcontrib>Polsky, B ; Kotler, D ; Steinhart, C</creatorcontrib><description>Wasting (malnutrition) and lipodystrophy are the two major nutritional alterations in human immunodeficiency virus (HIV)-infected individuals. Both wasting and lipodystrophy may involve a decrease in body fat content, while wasting-but not lipodystrophy-also includes the loss of lean body mass. Lipodystrophy has made the identification of wasting increasingly more difficult. The diagnosis of wasting depends on a definition of the condition that takes into account sex and cultural differences, as well as measurements of body cell mass. Patient management involves a concurrent, comprehensive approach designed to restore lost body cell mass and weight. The authors make recommendations for defining, diagnosing, and treating HIV-associated wasting. Specific therapies include testosterone replacement, other anabolic steroids, and recombinant human growth hormone. Other adjunctive measures, such as progressive resistance exercise and cytokine modulation, may also be utilized. Expected outcomes from effective treatment include restored body cell mass, improvement in quality of life, and reduced rates of hospitalization. Future directions for research should address the need for optimal treatment strategies.</description><identifier>ISSN: 1087-2914</identifier><identifier>EISSN: 1557-7449</identifier><identifier>DOI: 10.1089/108729101316914412</identifier><identifier>PMID: 11522215</identifier><identifier>CODEN: APACEF</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>AIDS/HIV ; Anabolic Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Clinical Trials as Topic ; Decision Trees ; Drug therapy ; highly active antiretroviral therapy ; HIV ; HIV Wasting Syndrome - diagnosis ; HIV Wasting Syndrome - prevention & control ; Human Growth Hormone - therapeutic use ; Human immunodeficiency virus ; Humans ; lipodystrophy ; Lipodystrophy - diagnosis ; Lipodystrophy - prevention & control ; Malnutrition ; Medical diagnosis ; Patients ; Physical Examination ; Practice Guidelines as Topic ; Testosterone - therapeutic use</subject><ispartof>AIDS patient care and STDs, 2001-08, Vol.15 (8), p.411-423</ispartof><rights>Copyright Mary Ann Liebert Inc. Aug 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-e38219ea69c4526f727829bcfbe705940efe52034f720d9b96f3acc981fb747f3</citedby><cites>FETCH-LOGICAL-c357t-e38219ea69c4526f727829bcfbe705940efe52034f720d9b96f3acc981fb747f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3042,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11522215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Polsky, B</creatorcontrib><creatorcontrib>Kotler, D</creatorcontrib><creatorcontrib>Steinhart, C</creatorcontrib><title>HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment</title><title>AIDS patient care and STDs</title><addtitle>AIDS Patient Care STDS</addtitle><description>Wasting (malnutrition) and lipodystrophy are the two major nutritional alterations in human immunodeficiency virus (HIV)-infected individuals. Both wasting and lipodystrophy may involve a decrease in body fat content, while wasting-but not lipodystrophy-also includes the loss of lean body mass. Lipodystrophy has made the identification of wasting increasingly more difficult. The diagnosis of wasting depends on a definition of the condition that takes into account sex and cultural differences, as well as measurements of body cell mass. Patient management involves a concurrent, comprehensive approach designed to restore lost body cell mass and weight. The authors make recommendations for defining, diagnosing, and treating HIV-associated wasting. Specific therapies include testosterone replacement, other anabolic steroids, and recombinant human growth hormone. Other adjunctive measures, such as progressive resistance exercise and cytokine modulation, may also be utilized. Expected outcomes from effective treatment include restored body cell mass, improvement in quality of life, and reduced rates of hospitalization. Future directions for research should address the need for optimal treatment strategies.</description><subject>AIDS/HIV</subject><subject>Anabolic Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Clinical Trials as Topic</subject><subject>Decision Trees</subject><subject>Drug therapy</subject><subject>highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV Wasting Syndrome - diagnosis</subject><subject>HIV Wasting Syndrome - prevention & control</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>lipodystrophy</subject><subject>Lipodystrophy - diagnosis</subject><subject>Lipodystrophy - prevention & control</subject><subject>Malnutrition</subject><subject>Medical diagnosis</subject><subject>Patients</subject><subject>Physical Examination</subject><subject>Practice Guidelines as Topic</subject><subject>Testosterone - therapeutic use</subject><issn>1087-2914</issn><issn>1557-7449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9LAzEQxYMotv75Ah4kePDU1Uw22Wy8laJWKAhSPQlLdndSI-1uTXYRv70pLQh68DIz8H5vYOYRcgbsCliur2NRXAODFDINQgDfI0OQUiVKCL0f5wgkkRADchTCO2Ms55IdkgGA5JyDHJLX6cNLYkJoK2c6rOmnCZ1rFtQ1tHtDOh2Pn-YUvbmhi97VuHQNBmpbT6MHQ1hh041o7cyiaYMLI2qamnYeTbdRTsiBNcuAp7t-TJ7vbueTaTJ7vH-YjGdJlUrVJZjmHDSaTFdC8swqrnKuy8qWqJjUgqFFyVkqosJqXerMpqaqdA62VELZ9JhcbveuffvRY-iKlQsVLpemwbYPhQLgqWD6XxByiO-ELIIXv8D3tvdNPKLgPMtVpDYQ30KVb0PwaIu1dyvjvwpgxSah4m9C0XS-29yXK6x_LLtI0m-wD4lX</recordid><startdate>20010801</startdate><enddate>20010801</enddate><creator>Polsky, B</creator><creator>Kotler, D</creator><creator>Steinhart, C</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20010801</creationdate><title>HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment</title><author>Polsky, B ; Kotler, D ; Steinhart, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-e38219ea69c4526f727829bcfbe705940efe52034f720d9b96f3acc981fb747f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>AIDS/HIV</topic><topic>Anabolic Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Clinical Trials as Topic</topic><topic>Decision Trees</topic><topic>Drug therapy</topic><topic>highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV Wasting Syndrome - diagnosis</topic><topic>HIV Wasting Syndrome - prevention & control</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>lipodystrophy</topic><topic>Lipodystrophy - diagnosis</topic><topic>Lipodystrophy - prevention & control</topic><topic>Malnutrition</topic><topic>Medical diagnosis</topic><topic>Patients</topic><topic>Physical Examination</topic><topic>Practice Guidelines as Topic</topic><topic>Testosterone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Polsky, B</creatorcontrib><creatorcontrib>Kotler, D</creatorcontrib><creatorcontrib>Steinhart, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS patient care and STDs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Polsky, B</au><au>Kotler, D</au><au>Steinhart, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment</atitle><jtitle>AIDS patient care and STDs</jtitle><addtitle>AIDS Patient Care STDS</addtitle><date>2001-08-01</date><risdate>2001</risdate><volume>15</volume><issue>8</issue><spage>411</spage><epage>423</epage><pages>411-423</pages><issn>1087-2914</issn><eissn>1557-7449</eissn><coden>APACEF</coden><abstract>Wasting (malnutrition) and lipodystrophy are the two major nutritional alterations in human immunodeficiency virus (HIV)-infected individuals. Both wasting and lipodystrophy may involve a decrease in body fat content, while wasting-but not lipodystrophy-also includes the loss of lean body mass. Lipodystrophy has made the identification of wasting increasingly more difficult. The diagnosis of wasting depends on a definition of the condition that takes into account sex and cultural differences, as well as measurements of body cell mass. Patient management involves a concurrent, comprehensive approach designed to restore lost body cell mass and weight. The authors make recommendations for defining, diagnosing, and treating HIV-associated wasting. Specific therapies include testosterone replacement, other anabolic steroids, and recombinant human growth hormone. Other adjunctive measures, such as progressive resistance exercise and cytokine modulation, may also be utilized. Expected outcomes from effective treatment include restored body cell mass, improvement in quality of life, and reduced rates of hospitalization. Future directions for research should address the need for optimal treatment strategies.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>11522215</pmid><doi>10.1089/108729101316914412</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-2914 |
| ispartof | AIDS patient care and STDs, 2001-08, Vol.15 (8), p.411-423 |
| issn | 1087-2914 1557-7449 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71123409 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | AIDS/HIV Anabolic Agents - therapeutic use Antiretroviral Therapy, Highly Active Clinical Trials as Topic Decision Trees Drug therapy highly active antiretroviral therapy HIV HIV Wasting Syndrome - diagnosis HIV Wasting Syndrome - prevention & control Human Growth Hormone - therapeutic use Human immunodeficiency virus Humans lipodystrophy Lipodystrophy - diagnosis Lipodystrophy - prevention & control Malnutrition Medical diagnosis Patients Physical Examination Practice Guidelines as Topic Testosterone - therapeutic use |
| title | HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A03%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HIV-associated%20wasting%20in%20the%20HAART%20era:%20guidelines%20for%20assessment,%20diagnosis,%20and%20treatment&rft.jtitle=AIDS%20patient%20care%20and%20STDs&rft.au=Polsky,%20B&rft.date=2001-08-01&rft.volume=15&rft.issue=8&rft.spage=411&rft.epage=423&rft.pages=411-423&rft.issn=1087-2914&rft.eissn=1557-7449&rft.coden=APACEF&rft_id=info:doi/10.1089/108729101316914412&rft_dat=%3Cproquest_cross%3E71123409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=226871016&rft_id=info:pmid/11522215&rfr_iscdi=true |